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Objectives: To assess health care professional’s judgments on economic con-
sequences of prescribed medical interventions and their responsiveness of 
different health care policy measures aiming for increasing their cost-conscious-
ness. MethOds: The design encompassed the nation-wide-cross-sectional hier-
archical levels of health care facilities across the geographical regions. Authors 
used validated and standardized Likert scale of Health Economic Awareness (HEA) 
adjusted for local setting to evaluate health care professionals by face-to-face inter-
views. The questionnaire comprehended clinician’sattitudes on: Clinical-Decision-
Making-Alternative-Interventions (CDMAI); Quality-of –Health-care (QHC); and 
Cost-Containment-Policy (CCP). This survey was conducted in two waves before 
and after policy intervention in 40 hospitals and primary care facilities in fifteen 
cities in Serbia from January 2010-December 2012. A total of 649 participants were 
interviewed before the intervention and 651 after the intervention. Core Republican 
Health Insurance Fund adopted and disseminated the package of cost containment 
measures through the Nation-wide pharmacoeconomic guidelines which princi-
pally targeted at prescribers. Pharmacists, physicians and dentists were examined 
by the scores of CDMAI, QHC, CCP and HEA. Results: Pharmacists and dentists 
had a higher average score (mean±s.d.) of CDMAI by the pharmacists (1.200±0.421) 
and the dentists (1.195±0.560) than the score of physicians (1.017±0.453). Dentists 
had the highest average score of CCP (2.127±0.598) and then the score of physicians 
(1.976±0.529). The score of pharmacists was the lowest (1.854±0.461).There were no 
impacts of the interventions on the professional behaviors regarding the scores 
of QHQ, CDMAI, CCP, and HEA. cOnclusiOns: Health economic awareness has 
differed substantially among of different health care professionals. Health policy 
measures were implemented to reduce non-cost-effective prescribing behaviors 
but the effects are non-clear-cut evidences. This experimental study is a pioneering 
effort in the wider Balkans region.
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Objectives: To assess the efficacy and safety of agomelatine using pharma-
covigilance during 12-week follow-up. MethOds: Agomelatine 25-50 mg was pre-
scribed open label to patients with depressive disorders diagnosed by psychiatrists 
based on DSM-IV/ICD-10 criteria. Treatment options were intent-to-treat. All 480 
patients, including 97 elderly patients were followed up at week 2 if dose titra-
tion was necessary. Efficacy was assessed using Montgomery-Äsberg Depression 
Rating Scale(MÄDRS) and clinical global impression of improvement (CGI-I) and of 
severity (CGI-S) scales, at weeks 2, 6, and 12. Data on adverse effects and for reports 
were gathered through patient interviews. Results: Of 480 patients, 20-86 years 
(mean[SD] 49.6[14.5]), 247(51.5%) were men and 97(20.2%) were elderly (65 to 86; 
mean[SD] 71.1[5.0]). Among all patients, 225(46.9%) and 255(53.1%) were depressed 
with a single episode and recurrent episodes. Patients with recurrent episodes were 
taking various classes of antidepressants, including selective serotonin reuptake 
inhibitors in 328(50.9%) patients. Generalized anxiety disorder was a concurrent 
diagnosis in 95(24.3%) of patients. The respective mean(SD) baseline CGI-S, CGI-I, 
and MADRS scores of 3.90(0.68), 4.15(0.76), and 22.59(3.77) were reduced to 2.1(0.31), 
1.11(0.37), and 9.19(2.03), with respective reductions in mean(SD; 95% CI) scores of 
1.78(0.75;1.72-1.85), 2.98(0.78;2.91-3.05), and 13.39(4.36; 13.00-13.78). Similar efficacy 
was evidenced for elderly depressed patients (N= 97), in whom mean(SD) MADRS 
score at baseline 22.37(4.79) was consistently significantly reduced to 14.61(3.04), 
10.76(3.04), and 8.72(1.91) at weeks 2, 6, and 12, respectively. After 12 weeks, over-
all remission (MADRS score < 10) was seen in 68.4% of patients with moderate to 
severe (MADRS > 25) depression and in 73.4% of elderly depressed patients. The 
mild adverse events reported were dizziness(9.5%), headache(7.4%), difficulty sleep-
ing(6.3%), and nausea(3.1%). There were no cases reported of alanine transaminase 
levels three times above upper limit of normal. cOnclusiOns: Agomelatine has 
proven to be a safe and effective new antidepressant in intent-to-treat analysis of 
depressed, including elderly, patients in daily clinical practice in Thailand.
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Objectives: Second generation antipsychotics (SGA) are associated with increased 
risk of metabolic side effects. A systematic literature review and mixed treatment 
comparisons (MTC) were performed to assess the efficacy and the metabolic side 
effects of antipsychotics, and more especially to compare lurasidone to other widely 
used antipsychotics in patient with acute schizophrenia. MethOds: This review 
included short-term (≤ 12 weeks) randomised controlled trials (RCTs) in patients 
with an acute phase of schizophrenia. The literature search was based on the 
NICE guidelines on treatment for schizophrenia published in 2010. A systematic 
search in the most comprehensive medical databases of peer-reviewed articles 
(MEDLINE, EMBASE, CENTRAL) was conducted until June 2012 to update the evi-
dence. In addition to lurasidone, eight comparators were considered: amisulpride, 
aripiprazole, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone and pla-
cebo. A Bayesian ramdom effect MTC was performed on efficacy outcomes (PANSS 
total score and CGI-S score) and metabolic side effects (weight, triglycerides, total 
cholesterol level and fasting glucose level). Results: Thirty-nine RCTs involving 
12,721 patients were included. Results showed that lurasidone had similar efficacy 
deviation] age 10.7 [2.75] years, 99% Caucasian, 82% male, 76% combined ADHD 
subtype). Variables associated with worsening severity were: baseline parental 
occupation (P= .003), poorer school outcomes (P< .001), and use of psychoeducation 
(P= .004). Initial use of nonstimulants (vs. stimulants) was associated with significant 
improvement on the CHIP-CE total score at 3 months and 9-24 months postbaseline. 
The estimated adjusted difference between treatments was −6.0 (95% confidence 
interval: −7.9, −4.1) at 24 months postbaseline. cOnclusiOns: In this observational 
study, worsening of ADHD symptoms was associated with initial use of psychoe-
ducation, parental occupation, and poorer school outcomes. Initial treatment with 
nonstimulants (vs. stimulants) was associated with improved QoL.
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Objectives: To assess the efficacy of a cognitive enhancer, donepezil, as an adju-
vant treatment to antipsychotics on clinical outcomes of schizophrenia. MethOds: 
Systematic review with meta-analysis to obtain appropriate evidence from rand-
omized clinical trials (RCTs) on the efficacy of donepezil plus antipsychotics versus 
placebo plus antipsychotics in patients diagnosed with schizophrenia for the follow-
ing outcomes: general psychopathology, positive/negative symptoms, and depres-
sive symptoms. Effect size estimates corrected for small sample size trials (Hedges’ 
g) were calculated for parallel trials and cross-over trials. Negative values for Hedges’ 
g denote an effect favouring the combined treatment. When needed, values for the 
cross-over correlation were imputed from available individual data to obtain the 
Hedges’ g estimates. The individual estimates were pooled with a random-effects 
meta-analysis. Results: Seven trials (4 cross-over, 3 parallel) were included. Four 
trials provided data on the Positive and Negative Syndrome Scale (PANSS) for total 
and general psychopathology scores. Three trials provided data for PANSS positive 
scores and 5 trials provided data for PANSS negative scores. Three trials provided 
data on depression scores. The combined treatment did not show differences in 
any of the assessed outcomes: PANSS total scores (g = -0.57, 95% CI = -2.11 to 0.96, 
I2 = 67%); PANSS General Psychopathology scores (g = -0.20, 95% CI = -0.74 to 0.34, 
I2 = 0%); PANSS positive symptoms (g = -0.06, 95% CI = -0.73 to 0.60, I2 = 0%); PANSS 
negative symptoms (g = -0.43, 95% CI = -1.98 to 1.12, I2 = 86%); depression scores (g = 
-0.35, 95% CI = -1.20 to 0.49, I2 = 0%). cOnclusiOns: The combination of donepezil 
with antipsychotic treatment does not improve clinical outcomes in schizophrenia.
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Objectives: Levomilnacipran (1S,2R-milnacipran) is a potent and selective seroto-
nin and norepinephrine reuptake inhibitor (SNRI) with approximately 2-fold greater 
potency for reuptake inhibition of norepinephrine than serotonin. Levomilnacipran 
SR is in late-stage clinical development for the treatment of major depressive dis-
order (MDD) in adults. A pooled analysis of Phase III studies was conducted to 
evaluate the effects of levomilnacipran SR treatment on functional health and 
well-being. MethOds: Pooled analysis of three double-blind, placebo-controlled, 
Phase III randomized clinical trials (Clinicaltrials.gov #NCT00969709, NCT00969150, 
NCT01034462), which included one fixed-dose (levomilnacipran SR 40, 80 or 120 mg/
day or placebo) and two flexible-dose (levomilnacipran SR 40-120 mg/day or placebo) 
studies that included the acute version of the SF-36v2 health survey. Percentage of 
responders following 8-weeks of treatment (observed cases) with levomilnacipran 
SR or placebo were compared for each individual health domain and the Physical 
(PCS) and Mental (MCS) Component Summary scores based on individual patient-
level responder criteria for minimally important differences. Estimates of odds 
ratios, 95% confidence intervals and p-values were from a logistic regression model 
with study and treatment as factors, baseline score as covariate and a study-by-
treatment interaction term. Results: Compared with placebo-treated patients, 
a greater percentage of patients who were treated with levomilnacipran SR were 
considered as responders. Homogeneity of OR could be assumed for the individual 
health domains and component summary scores except for the Bodily Pain scale 
(study-by-treatment interaction p-value= 0.0123). Pooled OR [95%-CI] for being a 
responder were as follows: MCS= 1.705 [1.292-2.250]; PCS= 1.285 [0.972-1.700]; General 
Health= 2.324 [1.763-3.064]; Social Functioning= 1.698 [1.295-2.226]; Vitality= 1.608 
[1.250-2.068]; Mental Health= 1.579 [1.203-2.072]; Role-Emotional= 1.453 [1.121-1.882]; 
Physical Functioning= 1.382 [1.032-1.850]; and Role-Physical= 1.341 [1.005-1.788]. All 
OR (except PCS) were statistically significant (p< 0.05). cOnclusiOns: Compared 
with placebo, patients who are treated with levomilnacipran SR are more likely to 
achieve meaningful improvement in multiple domains of health as measured by 
the SF-36 Health Survey.
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with newly diagnosed depressive disorder. The patients were followed up for one 
year after the index date (the first date of diagnosis). Psychotropic drugs used to 
treat depressive disorder included first- and/or second-generation antidepressant, 
benzodiazepine, sulpiride, and antipsychotics. The treatment duration and time to 
treatment by gender and age were evaluated by Cox regression model. Results: 
A total of 5,464 patients (men: 3,483, mean age: 36.1±9.9) with depressive disorder 
was identified. Median treatment duration was 123 days (men: 150 days, women 
92 days). 90.1% of patients was prescribed at least one psychotropic drug within 
30 days from the first date of diagnosis (84.5% in women and 93.1% in men). The 
proportion of patients who were prescribed at least one psychotropic drug for the 
first time after 6 months from the index date was 5.6% (men: 3.8%, women: 9.1%). 
The result showed that older patients were more likely to be treated longer period. 
In addition, men tend to be prescribed at least one psychotropic drug in a shorter 
period of time from the index date compared to that in women. cOnclusiOns: 
This study suggested the trend of treatment disparity between men and women as 
well as age in working population with regard to treatment duration and time to 
prescription. Further study is needed for generalizability.
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Objectives: PERFORM (Prospective Epidemiological Research on Functioning 
Outcomes Related to Major depressive disorder) is a 2-year prospective observa-
tional cohort study conducted in Europe (France, Germany, Spain, Sweden and UK). 
Objectives are to describe the functioning of patients with major depressive disorder 
(MDD) and factors associated with functional impairment. Here we compare charac-
teristics and outcomes of patients switching antidepressant treatment (ADT) with 
those initiating ADT at baseline, on an interim 1000-patient dataset. MethOds: 
Outpatients were recruited from primary or secondary care. Inclusion criteria were: 
DSM-IV-TR diagnosis of MDD, age 18-65 years, initiation or first switch to an ADT, in 
monotherapy. In addition to socio-demographics and disease history, data collec-
tion included clinician assessments (MADRS and CGI-S) and patient-rated scales 
evaluating depression (PHQ-9), functioning (SDS), work productivity (WPAI-SHP) 
and quality of life (QoL - EQ-5D). Results: Of 947 analysable patients at inclusion, 
213 (23%) patients were switching (76% for lack of efficacy), versus 716 (77%) initi-
ating ADT. Switchers were slightly older (mean age 46 versus 43 years) and more 
often female (77% vs. 72% women). Switching patients had more severe symptom 
profiles: more had previous depressive episodes (34% vs. 24%) and previous suicide 
attempts (16% vs. 12%). Severity of current episode was greater for switchers (46% 
vs. 36% with a CGI-S score above “markedly ill”; 48% versus 38% with a PHQ-9 score 
above the severe depression threshold). MADRS scores were similar: 18.1 versus 
17.6. QoL was poorer for switchers (EQ-5D: 0.449 vs. 0.567), as was overall patient 
functioning (47% vs. 36% with an SDS total score in the highest quartile), while no 
difference was found for absenteeism (35% vs. 34%) and presenteeism (49% vs. 50%) 
(WPAI-SHP). cOnclusiOns: Patients switching ADT had more severe symptom 
profiles, lower quality of life and higher functional impairment, compared to non-
switching patients.
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Objectives: PERFORM (Prospective Epidemiological Research on Functioning 
Outcomes Related to Major depressive disorder) is a 2-year prospective observa-
tional cohort study conducted in Europe to describe the functioning of patients 
with major depressive disorder (MDD) and factors associated with functional 
impairment. Here we report the impact of patient-reported cognitive dysfunc-
tion (PRCD) on quality of life (QoL), work and overall functioning at baseline, on 
a preliminary 1000-patient dataset. MethOds: Outpatients were recruited from 
primary or secondary care. Inclusion criteria were: DSM-IV-TR diagnosis of MDD, 
18-65 years old, initiation or first switch to an antidepressant, in monotherapy. 
Functioning was assessed by the SDS (Sheehan Disability Scale), work productiv-
ity by the WPAI-SHP (Work Productivity and Activity Impairment Questionnaire) 
and QoL by the EQ-5D (EuroQol-5 Dimensions) and SF-12 (12-Item Short-Form 
Health Survey). PRCD was assessed by the Perceived Deficit Questionnaire 5-item 
(PDQ-5). Descriptive analyses stratified on PDQ-5 quartiles were complemented 
with ANCOVA adjusted for severity of depression. Results: At inclusion, over 947 
analysable patients, mean PDQ-5 score (ranging from 0 to 20) was 11.5 (SD= 4.4). 
PRCD was associated with impairment of overall functioning, QoL and productiv-
ity. SDS total scores were 14.4, 18.5, 20.2, and 23.6 (first to fourth PDQ-5 quartiles, 
respectively) (p< 0.001). Similar patterns were observed for WPAI-SHP presentee-
ism scores (impairment while working: from 36.9% in first quartile to 64.4% in 
fourth quartile, p< 0.001; overall work impairment: from 41.5% to 71.3%, p< 0.001). 
These associations remained statistically significant after adjustment for baseline 
depression severity in multivariate analyses. A negative impact of PRCD was also 
observed on sick-leave length and on QoL. cOnclusiOns: At inclusion, subjective 
cognitive dysfunction in depressed patients was associated with poorer function-
ing, work productivity and QoL. This is in addition to any negative impact of the 
to others antipsychotics in terms of PANSS total score and CGI-S score and a similar 
effect as compared to placebo on all metabolic outcomes. The probability to have 
a lower impact than aripiprazole on weight increase and fasting glucose level was 
respectively 75.5% and 65.9%. Probabilities to have a lower impact on cholesterol 
level and triglycerides compared to olanzapine, quetiapine or riperidone varied 
from 98% to 100%. cOnclusiOns: Efficacy has been demonstrated for all reviewed 
treatments vs. placebo, with a similar effect. Lurasidone had a similar effect as 
compared to placebo and a less negative impact than olanzapine, quetiapine and 
risperidone on weight increase, triglycerides, total cholesterol level and than olan-
zapine on fasting glucose level.
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Objectives: Vortioxetine (Lu AA21004) is an investigative multimodal antide-
pressant which demonstrated efficacy, safety and tolerability in Major Depressive 
Episode (MDE). The comparison of vortioxetine to marketed antidepressants guides 
decison makers and clinicians in their choice of treatment. The main study objective 
was to generate comparative evidence for the efficacy and acceptability of vortiox-
etine in MDE. MethOds: Indirect comparisons were performed by meta-regression 
analysis, an extension of classical random-effect meta-analyses, to compare vorti-
oxetine to agomelatine, escitalopram, duloxetine, sertraline, venlafaxine IR/XR and 
vilazodone. To ensure comparability between studies, in terms of selection of patient 
population and exposure to treatment, only investigational drug and placebo arms 
from pre-registration placebo-controlled studies were included in the base case 
analyses. The main outcomes were efficacy, measured as the standardized mean dif-
ference between active treatment and placebo control in the change from baseline 
to 2 months of the primary endpoint (MADRS or HAM-D total score), and accept-
ability (the withdrawal rate due to adverse events) and expressed as the logarithm of 
the odds ratio (OR) between active treatment and placebo. Sensitivity analyses were 
performed with the inclusion of post-marketing authorization studies, adjustment 
for age/gender and on response and remission. Results: For efficacy, treatment 
effect estimates and p-values for vortioxetine versus comparators were: -0.16(0.11) 
versus agomelatine (negative effect favours vortioxetine); 0.09(0.42) versus dulox-
etine; -0.05(0.70) versus escitalopram; -0.04(0.83) versus sertraline; 0.12(0.33) versus 
venlafaxine IR/XR and -0.24(0.11) versus vilazodone. For acceptability, all but one OR 
(< 1) favoured vortioxetine: 1.77(0.03) versus agomelatine; 0.75(0.26) versus dulox-
etine; 0.67(0.28) versus escitalopram; 0.30(0.01) versus sertraline; 0.47(0.01) versus 
venlafaxine and 0.64(0.18) versus vilazodone. Meta-regression adjusted for age and 
gender demonstrated the robustness of the estimated differences between treat-
ments, as did sensitivity analyses including post-marketing trials. cOnclusiOns: 
Vortioxetine is a promising intervention with efficacy comparable to marketed anti-
depressants in MDE and a favourable acceptability profile.
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Objectives: The therapy of Attention Deficit/Hyperactivity Disorder (ADHD) with 
methylphenidate or atomoxetine, formerly only related to children and adolescents, 
is now extended to the adult population. Little is known about treatment patterns 
in Austria. The aim of this study was to evaluate the medication patterns of ADHD 
in 2012 in Austria, stratified by age and sex. MethOds: The data analysis refers to 
the accounting data of the 13 major Austrian health insurance funds, covering more 
than 97% of the Austrian population. Provided in a pseudonymised manner, with 
availability of the individual patient parameters age and sex, all dispensed medica-
tion of methylphenidate or atomoxetine is included in the descriptive analysis. The 
prevalence of ADHD medication is evaluated regarding age and sex. Furthermore the 
prescribed daily dose in relation to the defined daily dose is pointed out. Results: 
A total of 9120 patients with ADHD medication in 2012 are included in the analy-
sis (22% female). One per cent of all patients with ADHD medication is in the age 
cohort of under 6 years, 47% are between 6 and 13, 22% are between 14 and 17, and 
30% are adults (18+). The relation between the defined daily dose (ddd) to the pre-
scribed daily dose (pdd) shows that 86% of children and adolescents have less than 
366 pdd in the whole year and only 1% has more than 732 pdd. 81% of the adults 
have less than 366 pdd and 6% have more than 732 pdd. cOnclusiOns: While the 
variety of prescribed daily dose per patient is homogeneous during childhood and 
adolescence, this parameter spreads widely in adults. This could be an indicator of 
overuse or misuse. As the results reflect the prescription reality they can be used 
as a solid basis for further discussions, future evaluations and interventions about 
ADHD medication in Austria.
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Objectives: Treatment disparity by gender and age among patients with depres-
sive disorder in working population has not been examined in Japan. This study 
examined treatment disparity by gender and age among patients newly diagnosed 
with depressive disorder based on the claims database of health insurance socie-
ties between 2008 and 2011 in Japan. MethOds: Retrospective cohort database 
(N= 600,000) was followed up for four years to identify patients (18 ≤ age ≤ 65) 
